The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1
The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity
The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.
Recent Comments